^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Tazverik (tazemetostat) (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/25/2023
    Excerpt:
    Follicular Lymphoma….SECOND-LINE THERAPY FOR ELDERLY OR INFIRM….Other recommended regimens...Tazemetostat (irrespective of EZH2 mutation status)